The FDA has accepted Pharming Group’s supplemental new drug application for leniolisib in treating activated phosphoinositide ...

In the phase 1 portion of the trial, two doses of gedatolisib were administered IV on an intermittent schedule (Days 1, 8, 15 ...

Clinical benefit of the gedatolisib regimens was consistent across patient subgroups Hyperglycemia was reported in only 9.2% of patients treated ...

Clinical benefit of the gedatolisib regimens was consistent across patient subgroups Hyperglycemia was reported in only 9.2% of patients treated with gedatolisib + palbociclib + fulvestrant ...

FMC-242 is a potentially best-in-class covalent allosteric inhibitor that breaks the interaction between PI3Kα and RAS, ...

Endocrine therapy typically slows cell cycle progression by reducing cyclin D1, which partners with CDK4/6 to promote cell ...

Researchers demonstrated that pancreatic β cells from type 2 diabetes donors can partially regain glucose responsiveness when ...

Gedatolisib combined with fulvestrant, with or without palbociclib, significantly improved PFS in HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer. The triplet regimen reduced ...

The new funds will allow the company to test its multi-node PI3K treatment approach in a new endometrial cancer trial.